Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $132.00 Price Target at Citizens Jmp

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target reduced by Citizens Jmp from $140.00 to $132.00 in a report issued on Thursday morning,Benzinga reports. They currently have a market outperform rating on the stock.

MIRM has been the topic of several other research reports. TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Royal Bank Of Canada initiated coverage on Mirum Pharmaceuticals in a report on Tuesday, February 17th. They set an “outperform” rating and a $130.00 target price on the stock. HC Wainwright upped their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Stifel Nicolaus lifted their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $114.92.

Mirum Pharmaceuticals Stock Down 15.1%

MIRM opened at $92.19 on Thursday. The stock’s 50 day moving average price is $93.11 and its 200 day moving average price is $78.90. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The stock has a market cap of $4.74 billion, a P/E ratio of -192.06 and a beta of 0.49. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The business had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.98% and a negative net margin of 4.48%.The company’s revenue for the quarter was up 49.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.00 EPS. As a group, research analysts predict that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $940,856.40. Following the transaction, the chief executive officer directly owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Eric Bjerkholt sold 1,421 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $132,621.93. Following the sale, the chief financial officer directly owned 42,127 shares in the company, valued at $3,931,712.91. This trade represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,136 shares of company stock valued at $4,352,029 in the last 90 days. 14.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MIRM. CWM LLC lifted its stake in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after purchasing an additional 176 shares during the period. MCF Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after purchasing an additional 200 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock worth $504,000 after purchasing an additional 215 shares during the period.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue beat and strong product growth—Mirum posted ~50% y/y revenue growth driven by Livmarli and other bile-acid therapies, beating Street revenue estimates, which supports the company’s top-line trajectory. Article Title
• Positive Sentiment: Corporate release and call provide detail and FY revenue guide—Mirum’s press release and earnings call outlined operations and gave FY2026 revenue guidance ($630M–$650M), offering a revenue roadmap for investors even as EPS guidance/detail was limited. Article Title
• Positive Sentiment: Analysts largely remain bullish — multiple firms raised or reiterated positive ratings and targets (TD Cowen, Stifel Nicolaus, RBC and others continue to show upside vs. the current price), signaling analyst confidence in longer-term upside despite short-term noise. Article Title
• Neutral Sentiment: Transcripts and analysis available—Earnings-call transcripts and analyst writeups (Seeking Alpha, The Motley Fool, Zacks) give more color for investors deciding whether the EPS miss is a one-off or structural. Use these to dig into margins, SG&A, and commercial execution details. Article Title Article Title
• Negative Sentiment: EPS miss and margin concerns—Mirum reported ($0.11) EPS vs. a ~$0.02 consensus, a significant miss that triggered the selloff despite the revenue beat; investors are focused on margins, profitability timeline, and whether EPS guidance will be conservative. Article Title
• Negative Sentiment: Immediate market reaction and volume—Coverage and commentary (AAII and others) point to the EPS miss + any perceived conservative guidance as the proximate cause of today’s decline; heavy volume suggests short-term technical selling even as analysts debate the longer-term story. Article Title

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.